"Zanamivir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.
| Descriptor ID |
D053243
|
| MeSH Number(s) |
D02.078.370.926 D02.241.081.844.562.668.775 D02.241.511.902.562.668.775 D03.383.663.859 D09.067.687.668.775 D09.811.589.668.775
|
| Concept/Terms |
Zanamivir- Zanamivir
- 2,3-Didehydro-2,4-Dideoxy-4-Guanidinyl-N-Acetylneuraminic Acid
- 4-Guanidino-2,4-Dideoxy-2,3-Didehydro-N-Acetylneuraminic Acid
- 5-Acetylamino-2,6-Anhydro-4-Guanidino-3,4,5-Trideoxy-D-Galacto-Non-Enoic Acid
- 4-Guanidino-Neu5Ac2en
- 4 Guanidino Neu5Ac2en
- 2,3-Didehydro-2,4-Dideoxy-4-Guanidino-N-Acetyl-D-Neuraminic Acid
- 4-Guanidino-2-Deoxy-2,3-Didehydro-N-Acetylneuraminic Acid
- 4 Guanidino 2 Deoxy 2,3 Didehydro N Acetylneuraminic Acid
- Acid, 4-Guanidino-2-Deoxy-2,3-Didehydro-N-Acetylneuraminic
|
Below are MeSH descriptors whose meaning is more general than "Zanamivir".
Below are MeSH descriptors whose meaning is more specific than "Zanamivir".
This graph shows the total number of publications written about "Zanamivir" by people in this website by year, and whether "Zanamivir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 3 | 5 | 8 |
| 2018 | 5 | 2 | 7 |
| 2019 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Zanamivir" by people in Profiles.
-
Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. Antiviral Res. 2021 10; 194:105158.
-
Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis. JAMA Netw Open. 2021 08 02; 4(8):e2119151.
-
Probing antiviral drugs against SARS-CoV-2 through virus-drug association prediction based on the KATZ method. Genomics. 2020 11; 112(6):4427-4434.
-
A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020 May - Jun; 35:101646.
-
Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives. Expert Opin Pharmacother. 2019 Oct; 20(14):1711-1718.
-
Clinical management and viral genomic diversity analysis of a child's influenza A(H1N1)pdm09 infection in the context of a severe combined immunodeficiency. Antiviral Res. 2018 12; 160:1-9.
-
Triple combination of FDA-approved drugs including flufenamic acid, clarithromycin and zanamivir improves survival of severe influenza in mice. Arch Virol. 2018 Sep; 163(9):2349-2358.
-
Clinicians' attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza. BMC Health Serv Res. 2018 05 02; 18(1):311.
-
Zanamivir Diminishes Lung Damage in Influenza A Virus-infected Mice by Inhibiting Nitric Oxide Production. In Vivo. 2018 May-Jun; 32(3):473-478.
-
A Sulfonozanamivir Analogue Has Potent Anti-influenza Virus Activity. ChemMedChem. 2018 04 23; 13(8):785-789.